Korsana Biosciences, Inc. — Form SCHEDULE 13D
Filed September 15, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., and Venrock Healthcare Capital Partners XP, L.P., along with individuals Bong Koh and Nimish Shah, filed a joint Schedule 13D on September 15, 2026, for Korsana Biosciences common stock. The filing establishes powers of attorney for Jessica Baron, Evan W. Neu, and Sherman G. Souther, Jr. to execute SEC filings and amendments on behalf of the filers. No specific shareholding percentages, dollar amounts, or share counts are disclosed in these exhibits.
Why this rating
Standard Schedule 13D filing mechanics with no disclosed stake size, acquisition details, or material transaction. Without shareholding data relative to $5.7M market cap, cannot assess materiality of position.
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.